CD4+ T Cell-Associated Pathophysiology Critically Depends on CD18 Gene Dose Effects in a Murine Model of Psoriasis

Journal of Immunology

Volumn 171, Issue 11, 2003, Pages 5697-5706

  Kess, Daniel ^a,d   Peters, Thorsten ^a,d   Zamek, Jan ^a   Wickenhauser, Claudia ^a   Tawadros, Samir ^a   Loser, Karin ^b   Varga, Georg ^b   Grabbe, Stephan ^b   Nischt, Roswitha ^a   Sunderkötter, Cord ^b,d   Müller, Werner ^c   Krieg, Thomas ^a   Scharffetter Kochanek, Karin ^a,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; SKIN ALLERGY; SKIN BLOOD VESSEL; SKIN INFLAMMATION; T LYMPHOCYTE; TH1 CELL; WILD TYPE;

EID: 10744227499     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.11.5697     Document Type: Article

References (75)

1. Anderson, D. C., L. J. Miller, F. C. Schmalstieg, R. Rothlein, and T. A. Springer. 1986. Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. J. Immunol. 137:15.
2. Hynes, R. O. 1987. Integrins: a family of cell surface receptors. Cell 48:549.
3. Arnaout, M. A. 1990. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037.
4. 2, binds preferentially to ICAM-3. Immunity 3:683.
5. Carlos, T. M., and J. M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. Blood 84:2068.
6. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301.
7. Beatty, P. G., H. D. Ochs, J. M. Harlan, T. H. Price, H. Rosen, R. F. Taylor, J. A. Hansen, and S. J. Klebanoff. 1984. Absence of monoclonal-antibody-defined protein complex in boy with abnormal leukocyte function. Lancet 1:535.
8. Kishimoto, T. K., N. Hollander, T. M. Roberts, D. C. Anderson, and T. A. Springer. 1987. Heterogeneous mutations in the β subunit common to the LFA-1, Mac-1, and p150, 95 glycoproteins cause leukocyte adhesion deficiency. Cell 50:193.
9. Kuijpers, T. W., R. A. Van Lier, D. Hamann, M. de Boer, L. Y. Thung, R. S. Weening, A. J. Verhoeven, and D. Roos. 1997. Leukocyte adhesion deficiency type 1 (LAD-1)/variant: a novel immunodeficiency syndrome characterized by dysfunctional β2 integrins. J. Clin. Invest. 100:1725.
10. Anderson, D. C., T. K. Kishimoto, and C. W. Smith. 1995. Leukocyte Adhesion Deficiency and Other Disorders of Leukocyte Adherence and Motility. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, eds. McGraw-Hill, New York, p. 3955.
11. Anderson, D. C., F. C. Schmalsteig, M. J. Finegold, B. J. Hughes, R. Rothlein, L. J. Miller, S. Kohl, M. F. Tosi, R. L. Jacobs, T. C. Waldrop, et al. 1985. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J. Infect. Dis. 152:668.
12. Rothlein, R., and T. A. Springer. 1986. The requirement for lymphocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester. J. Exp. Med. 163:1132.
13. Koopman, G., M. de Graaff, A. C. Huysmans, C. J. Meijer, and S. T. Pals. 1992. Induction of homotypic T cell adhesion by triggering of leukocyte function-associated antigen-1α (CD11a): differential effects on resting and activated T cells. Eur. J. Immunol. 22:1851.
14. Mentzer, S. J., S. H. Gromkowski, A. M. Krensky, S. J. Burakoff, and E. Martz. 1985. LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytes. J. Immunol. 135:9.
15. Davignon, D., E. Martz, T. Reynolds, K. Kurzinger, and T. A. Springer. 1981. Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): mechanism of blockade of T lymphocyte-mediated killing and effects on other T and B lymphocyte functions. J. Immunol. 127:590.
16. Bachmann, M. F., K. McKall-Faienza, R. Schmits, D. Bouchard, J. Beach, D. E. Speiser, T. W. Mak, and P. S. Ohashi. 1997. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 7:549.
17. Scharffetter-Kochanek, K., H. Lu, K. Norman, N. van Nood, F. Munoz, S. Grabbe, M. McArthur, I. Lorenzo, S. Kaplan, K. Ley, et al. 1998. Spontaneous skin ulceration and defective T cell function in CD18 null mice. J. Exp. Med. 188:119.
18. Schönlau, F., K. Scharffetter-Kochanek, S. Grabbe, B. Pietz, C. Sorg, and C. Sunderkötter. 2000. In experimental leishmaniasis deficiency of CD 18 results in parasite dissemination associated with altered macrophage functions and incomplete Th1 cell response. Eur. J. Immunol. 30:2729.
19. 2 integrin leukocyte function-associated antigen-1. J. Immunol. 157:5375.
20. 2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J. Clin. Invest. 109:183.
21. Wilson, R. W., C. M. Ballantyne, C. W. Smith, C. Montgomery, A. Bradley, W. E. O'Brien, and A. L. Beaudet. 1993. Gene targeting yields a CD18-mutant mouse for study of inflammation. J. Immunol. 151:1571.
22. Bullard, D. C., K. Scharffetter-Kochanek, M. J. McArthur, J. G. Chosay, M. E. McBride, C. A. Montgomery, and A. L. Beaudet. 1996. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc. Natl. Acad. Sci. USA 93:2116.
23. Feldman, S. R., S. M. Ravis, A. B. Fleischer, Jr., A. McMichael, E. Jones, R. Kaplan, J. Shavin, J. Weiss, J. K. Bartruff, D. L. Levin, et al. 2001. Beta-methasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J. Cutan. Med. Surg. 5:386.
24. Van de Kerkhof, P. C., and M. E. Franssen. 2001. Psoriasis of the scalp: diagnosis and management. Am. J. Clin. Dermatol. 2:159.
25. Lebwohl, M., and S. Ali. 2001. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J. Am. Acad. Dermatol. 45:487.
26. Nickoloff, B. J., J. M. Schroder, P. von den Driesch, S. P. Raychaudhuri, E. M. Farber, W. H. Boehncke, V. B. Morhenn, E. W. Rosenberg, M. P. Schon, and M. F. Holick. 2000. Is psoriasis a T-cell disease? Exp. Dermatol. 9:359.
27. Krueger, J. G. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46:1.
28. Ellis, C. N., and G. G. Krueger. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345:248.
29. Morel, P., J. P. Revillard, J. F. Nicolas, J. Wijdenes, H. Rizova, and J. Thivolet. 1992. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. 5:465.
30. Bachelez, H., B. Flageul, L. Dubertret, S. Fraitag, R. Grossman, N. Brousse, D. Poisson, R. W. Knowles, M. C. Wacholtz, T. P. Haverty, et al. 1998. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11:53.
31. Gottlieb, A. B., M. Lebwohl, S. Shirin, A. Sherr, P. Gilleaudeau, G. Singer, G. Solodkina, R. Grossman, E. Gisoldi, S. Phillips, et al. 2000. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J. Am. Acad. Dermatol. 43:595.
32. Gottlieb, S. L., P. Gilleaudeau, R. Johnson, L. Estes, T. G. Woodworth, A. B. Gottlieb, and J. G. Krueger. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442.
33. Bagel, J., W. T. Garland, D. Breneman, M. Holick, T. W. Littlejohn, D. Crosby, H. Faust, D. Fivenson, and J. Nichols. 1998. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J. Am. Acad. Dermatol. 38:938.
34. Krueger, J. G., I. B. Walters, M. Miyazawa, P. Gilleaudeau, J. Hakimi, S. Light, A. Sherr, and A. B. Gottlieb. 2000. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43:448.
35. Owen, C. M., and P. V. Harrison. 2000. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. 25:195.
36. Mrowietz, U., K. Zhu, and E. Christophers. 2000. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch. Dermatol. 136:675.
37. Abrams, J. R., M. G. Lebwohl, C. A. Guzzo, B. V. Jegasothy, M. T. Goldfarb, B. S. Goffe, A. Menter, N. J. Lowe, G. Krueger, M. J. Brown, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103:1243.
38. Papp, K., R. Bissonnette, J. G. Krueger, W. Carey, D. Gratton, W. P. Gulliver, H. Lui, C. W. Lynde, A. Magee, D. Minier, et al. 2001. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. 45:665.
39. Gottlieb, A., J. G. Krueger, R. Bright, M. Ling, M. Lebwohl, S. Kang, S. Feldman, M. Spellman, K. Wittkowski, H. D. Ochs, et al. 2000. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42:428.
40. Neumuller, J., A. Dunky, H. Burtscher, R. Jilch, and J. E. Menzel. 2001. Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin. Immunol. 98:143.
41. Van Pelt, J. P. A., E. M. G. J. De Jong, P. E. J. van Erp, and P. C. M. van de Kerkhof. 1997. Decreased CD11b expression on circulating polymorphonuclear leukocytes in patients with extensive plaque psoriasis. Eur. J. Dermatol. 7:324.
42. Van de Kerkhof, P. C., and C. M. Weemaes. 1990. Skin manifestations in congenital deficiency of leukocyte-adherence glycoproteins (CDLG). Br. J. Dermatol. 123:395.
43. Tomfohrde, J., A. Silverman, R. Barnes, M. A. Fernandez-Vina, M. Young, D. Lory, L. Morris, K. D. Wuepper, P. Stastny, A. Menter, et al. 1994. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science 264:1141.
44. Gencik, M., S. Meller, S. Borgmann, T. Sitter, A. M. Menezes Saecker, H. Fricke, and J. T. Epplen. 2000. The association of CD18 alleles with antimyeloperoxidase subtypes of ANCA-associated systemic vasculitides. Clin. Immunol. 94:9.
45. + vasculitis. Genes Immun. 2:269.
46. Sunderkötter, C., W. Beil, J. Roth, and C. Sorg. 1991. Cellular events associated with inflammatory angiogenesis in the mouse cornea. Am. J. Pathol. 138:931.
47. Grabbe, S., K. Steinbrink, M. Steinert, T. A. Luger, and T. Schwarz. 1995. Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity. J. Immunol. 155:4207.
48. Grabbe, S., M. Steinert, K. Mahnke, A. Schwartz, T. A. Luger, and T. Schwarz. 1996. Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice: evidence that not the antigenic component but nonspecific proinflammatory effects of haptens determine the concentration-dependent elicitation of allergic contact dermatitis. J. Clin. Invest. 98:1158.
49. Lisowska-Grospierre, B., M. C. Bohler, A. Fischer, C. Mawas, T. A. Springer, and C. Giscelli. 1986. Defective membrane expression of the LFA-1 complex may be secondary to the absence of the β chain in a child with recurrent bacterial infection. Eur. J. Immunol. 16:205.
50. Dimanche, M. T., F. Le Deist, A. Fischer, M. A. Arnaout, C. Griscelli, and B. Lisowska-Grospierre. 1987. LFA-1 β-chain synthesis and degradation in patients with leukocyte-adhesive proteins deficiency. Eur. J. Immunol. 17:417.
51. Lin, W. J., D. A. Norris, M. Achziger, B. L. Kotzin, and B. Tomkinson. 2001. Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions. J. Invest. Dermatol. 117:1546.
52. Prinz, J. C. 2001. Psoriasis vulgaris: a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin. Exp. Dermatol. 26:326.
53. Valdimarsson, H., B. S. Baker, I. Jonsdottir, A. Powles, and L. Fry. 1995. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today 16:145.
54. Thivolet, J., and J. F. Nicolas. 1994. Immunointervention in psoriasis with anti-CD4 antibodies. Int. J. Dermatol. 33:327.
55. Schlaak, J. F., M. Buslau, W. Jochum, E. Hermann, M. Girndt, H. Gallati, K. H. Meyer zum Buschenfelde, and B. Fleischer. 1994. T cells involved in psoriasis vulgaris belong to the Th1 subset. J. Invest. Dermatol. 102:145.
56. Austin, L. M., M. Ozawa, T. Kikuchi, I. B. Walters, and J. G. Krueger. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TCl (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113:752.
57. Prinz, J. 1997. Psoriasis vulgaris: der lange Weg zur Autoimmunerkrankung. In Fortschritte der praktischen Dermatologie und Venerologie. G. Plewig and B. Przybilla, eds. Springer. Berlin, Heidelberg, p. 21.
58. Nickoloff, B. J. 1999. The immunologic and genetic basis of psoriasis. Arch. Dermatol. 135:1104.
59. Breathnach, S. M., and W. G. Phillips. 1996. Psoriasis. In Cytokines in Autoimmunity. F. M. Brennan and M. Feldmann, eds. R. G. Landes Company, Austin, p. 175.
60. Ghoreschi, K., P. Thomas, S. Breit, T. Biedermann, J. Prinz, C. Sander, G. Plewig, and M. Röcken. 2001. Interleukin 4-induced immune deviation as therapy for psoriasis. J. Invest. Dermatol. 117:465.
61. Ghoreschi, K., P. Thomas, S. Breit, M. Dugas, R. Mailhammer, W. Van Eden, R. Van Der Zee, T. Biedermann, J. Prinz, M. Mack, et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40.
62. Asadullah, K., W. D. Docke, M. Ebeling, M. Friedrich, G. Belbe, H. Audring, H. D. Volk, and W. Sterry. 1999. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch. Dermatol. 135:187.
63. Trepicchio, W. L., M. Ozawa, I. B. Walters, T. Kikuchi, P. Gilleaudeau, J. L. Bliss, U. Schwertschlag, A. J. Dorner, and J. G. Krueger. 1999. Interleukin-11 therapy selectively down-regulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104:1527.
64. Ross, G. D., R. A. Thompson, M. J. Walport, T. A. Springer, J. V. Watson, R. H. Ward, J. Lida, S. L. Newman, R. A. Harrison, and P. J. Lachmann. 1985. Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1. Blood 66:882.
65. Springer, T. A., W. S. Thompson, L. J. Miller, F. C. Schmalstieg, and D. C. Anderson. 1984. Inherited deficiency of the Mac-1, LFA-1, p150, 95 glycoprotein family and its molecular basis. J. Exp. Med. 160:1901.
66. Fine, J. S., and A. M. Kruisbeek. 1991. The role of LFA-1/ICAM-1 interactions during murine T lymphocyte development. J. Immunol. 147:2852.
67. Quddus, J., A. Kaplan, and B. C. Richardson. 1994. Anti-CD11a prevents deletion of self-reactive T cells in neonatal C57BR mice. Immunology 82:301.
68. Ferrero, I., F. Anjuere, P. Martin, G. Martinez del Hoyo, M. L. Fraga, N. Wright, R. Varona, G. Marquez, and C. Ardavin. 1999. Functional and phenotypic analysis of thymic B cells: role in the induction of T cell negative selection. Eur. J. Immunol. 29:1598.
69. 2m: an animal model of HLA-B27-associated human disorders. Cell 63:1099.
70. + T cells. Nat. Med. 3:183.
71. Pasparakis, M., G. Courtois, M. Hafner, M. Schmidt-Supprian, A. Nenci, A. Toksoy, M. Krampert, M. Goebeler, R. Gillitzer, A. Israel, et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417:861.
72. Carroll, J. M., M. R. Romero, and F. M. Watt. 1995. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 83:957.
73. Boehncke, W. H., W. Sterry, A. Hainzl, W. Scheffold, and R. Kaufmann. 1994. Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. Arch. Dermatol. Res. 286:325.
74. Mehling, A., K. Loser, G. Varga, D. Metze, T. A. Luger, T. Schwarz, S. Grabbe, and S. Beissert. 2001. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J. Exp. Med. 194:615.
75. Sato, S., M. Hasegawa, M. Fujimoto, T. F. Tedder, and K. Takehara. 2000. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165:6635.